Skip to content

FINALITY-HF

Heart Failure | CHF

People with chronic heart failure are often prescribed medications to help manage their condition. This study is testing how well a drug called finerenone works and how safe it is for people with heart failure who cannot take a class of medications known as mineralocorticoid receptor antagonists (MRAs). MRAs are commonly used in treating heart failure, but some patients can't use them due to side effects or other health issues. This study is looking at whether finerenone which is a newer MRA medication could be a good alternative for those patients.

null

Conditions de participation

  • Sexe:

    Female, Any, Male

  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:
Provide electronic or written informed consent.
Age ≥18 years
Must not have a history of problems with a class of medications(MRAs) like spironolactone or eplerenone. This could include previous side effects (intolerance) or situations where these medications shouldn't be used (contraindications).
Other inclusion criteria also exist, and the diagnosis of heart failure should be confirmed by a physician.
Exclusion Criteria:
Patients with heart failure and an ejection fraction below 40%
Several exclusions including contraindications to these classes of medications

Lieu de l'étude

University of Alberta
University of Alberta
Edmonton, Alberta
Canada

Contactez l'équipe d'étude

Étude parrainée par
University of Alberta
Participants recherchés
Plus d'informations
ID de l'étude: Pro00148010